Arrotex and Pfizer Australia Announce Strategic Partnership for ENBREL Distribution

New Commercial Alliance Formed

Arrotex Pharmaceuticals and Pfizer Australia have officially announced a new strategic commercial partnership concerning the biologic therapy ENBREL (etanercept). The agreement, which became effective on February 1, 2026, designates Arrotex as the representative for ENBREL across Australian community and hospital pharmacy channels, as well as within prescriber networks.

Enhancing Access to ENBREL

Under the terms of the partnership, Arrotex will assume responsibility for the commercial representation of ENBREL, a well-established biologic therapy used to treat a variety of autoimmune conditions in both adult and pediatric patients. These conditions include

• rheumatoid arthritis
• psoriatic arthritis
• ankylosing spondylitis
• plaque psoriasis

. ENBREL functions as a tumor necrosis factor (TNF) inhibitor, interfering with the inflammatory response of the immune system.

Pfizer Australia and New Zealand Managing Director Anne Harris stated that the decision to partner with Arrotex was based on the latter's 'demonstrated ability to deliver national scale, strong distribution capability and disciplined commercial execution'. This move also signifies Pfizer's commitment to further engage with and invest in the community pharmacy sector, recognizing its growing influence in Australia's healthcare landscape.

Strategic Benefits for Pharmacy Channels

For Arrotex, this collaboration marks its 'first partnership with Pfizer' and represents an 'important milestone' for the organization, as noted by Arrotex Chief Commercial Officer Hayley Tamborini. Tamborini highlighted that integrating a Pfizer-partnered product into the Arrotex platform would generate 'additional commercial value to pharmacies', particularly since ENBREL had not previously been part of such programs. Arrotex sales representatives have already begun engaging with aligned pharmacies nationwide.

Arrotex Pharmaceuticals, formed in 2019 from the merger of Arrow Pharmaceuticals and Apotex Australia, is recognized as Australia's largest and most diversified pharmaceutical company. The company aims to provide affordable access to quality products and improve health outcomes for Australians. Pfizer Australia is a prominent biopharmaceutical company with a broad portfolio of medicines, vaccines, and therapeutics.